Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: Comparison with silymarin

Cancer Letters

Volumn 147, Issue 1-2, 1999, Pages 77-84

  Bhatia, Neehar ^a   Zhao, Jifu ^a   Wolf, Douglas M ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Chemoprevention; Silibinin; Silymarin

Indexed keywords

SILIBININ; SILYMARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; STEREOISOMERISM; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; CELL SURVIVAL; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NUCLEIC ACID SYNTHESIS INHIBITORS; PROSTATIC NEOPLASMS; SILYMARIN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; UTERINE CERVICAL NEOPLASMS;

CIRSIUM; SILYBUM;

EID: 0032727651     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00276-1     Document Type: Article

References (38)

1. Cancer Facts and Figures. 1998;American Cancer Society Inc.
2. Agarwal R., Mukhtar H. Chemoprevention of photocarcinogenesis. Photochem. Photobiol. 63:1996;440-444.
3. Ames B.N., Gold L.S., Willett W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA. 92:1995;5258-5265.
4. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R., Sigman C.C. Chemopreventive drug development: prospectives and progress. Cancer Epidemiol. Biomarkers Prev. 3:1994;85-98.
5. Kelloff G.J., Boone C.W., Crowell J.A., Nayfield S.G., Hawk E., Malone W.F., Steele V.E., Lubet R.A., Sigman C.C. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem. 25:(Suppl.):1996;1-14.
6. Birt D.F., Pelling J.C., Nair S., Lepley D. Diet intervention for modifying cancer risk. Prog. Clin. Biol. Res. 395:1996;223-234.
7. Morse M.A., Stoner G.D., ancer C. chemoprevention: principles and prospects. Carcinogenesis. 14:1993;1737-1746.
8. Lipkin M. New rodent models for studies of chemopreventive agents. J. Cell. Biochem. 28-29:(Suppl.):1997;144-147.
9. Conney A.H., Lou Y.R., Xie J.G., Osawa T., Newmark H.L., Liu Y., Chang R.L., Huang M.T. Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea. Proc. Soc. Exp. Biol. Med. 216:1997;234-245.
10. Goodman G.E. The clinical evaluation of cancer prevention agents. Proc. Soc. Exp. Biol. Med. 216:1997;253-259.
11. Boone C.W., Bacus J.W., Bacus J.V., Steele V.E., Kelloff G.J. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents. J. Cell. Biochem. Suppl. 28-29:1997;1-20.
12. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science. 278:1997;1073-1077.
13. Wattenberg L.W. An overview of chemoprevention: current status and future prospects. Proc. Soc. Exp. Biol. Med. 216:1997;133-141.
14. Perchellet J.P., Perchellet E.M. Antioxidants and multistage carcinogenesis in mouse skin. Free Radic. Biol. Med. 7:1989;377-408.
15. Dragsted L.O. Natural antioxidants in chemoprevention. Arch. Toxicol. Suppl. 20:1998;209-226.
16. Mukhtar H., Agarwal R. Skin cancer chemoprevention. J. Invest. Dermatol. Sym. Proc. 1:1996;209-214.
17. Kensler T.W., Taffe B.G. Role of free radicals in tumor promotion and progression. Prog. Clin. Biol. Res. 298:1989;233-248.
18. Lahiri M., Mukhtar H., Agarwal R. Reactive intermediates and skin cancer. Kitchin K.T. Carcinogenicity: Testing, Predicting, and Interpreting Chemical Effects. 1999;679-714 Marcel Dekker, New York.
19. Wagner H., Seligmann O., Horhammer L., Munster R. The chemistry of silymarin (silybin), the active principle of the fruits of Silybum marianum (L) Gaertn (Carduus marianus) (L). Arzneim.-Forsch. 18:1968;688-696.
20. Wagner V.H., Diesel P., Seitz M. Chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneim.-Forsch. 24:1974;466-471.
21. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern. Med. Rev. 3:1998;410-421.
22. Letteron P., Labbe G., Degott C., Berson A., Fromenty B., Delaforge M. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem. Pharmacol. 39:1990;2027-2034.
23. Mereish K.A., Bunner D.L., Ragland D.R., Creasia D.A. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharm. Res. 8:1991;273-277.
24. 4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol. 3:1989;183-191.
25. Valenzuela A., Guerra R., Videla L.A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med. 52:1986;438-440.
26. Comoglio A., Leonarduzzi G., Carini R., Busolin D., Basaga H., Albano E. Studies on the antioxidant and free radical scavenging properties of IdB1016 a new flavanolignan complex. Free Radic. Res. Commun. 11:1990;109-115.
27. Vogel G., Trost W., Braatz R. Studies on the pharmacodynamics, including site and mode of action, of silymarin: the antihepatotoxic principle from Silybum marianum (L) Gaertn. Arzneim.-Forsch. 25:1975;82-89.
28. Hahn V.G., Lehmann H.D., Kurten M., Uebel H., Vogel G. Pharmacology and toxicology of silymarin, the anti-hepatotoxic agent of Silybum marianum (L) Gaertn. Arzneim.-Forsch. 18:1968;698-704.
29. Ely H. Dermatologic therapies you've probably never heard of. Dermatol. Clin. 7:1989;19-35.
30. Agarwal R., Katiyar S.K., Lundgren D.W., Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis. 15:1994;1099-1103.
31. Katiyar S.K., Korman N.J., Mukhtar H., Agarwal R. Protective effects of silymarin against photocarcinogenesis in mouse skin model. J. Natl. Cancer Inst. 89:1997;556-566.
32. Zi X., Mukhtar H., Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFα Biochem. Biophys. Res. Commun. 239:1997;334-339.
33. Zi X., Feyes D.K., Agarwal R. Anti-carcinogenic effect of a flavonoid antioxidant silymarin in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of CDKs and associated cyclins. Clin. Cancer Res. 4:1998;1055-1064.
34. Zi X., Grasso A.W., Kung H.J., Agarwal R. flavonoid antioxidant silymarin inhibits activation of erbB1 signaling, and induces cyclin-dependent kinase inhibitors, G1 arrest and anti-carcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 58:1998;1920-1929.
35. Ahmad N., Gali H., Javed S., Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem. Biophys. Res. Commun. 248:1998;294-301.
36. Lahiri-Chatterjee M., Katiyar S.K., Mohan R.R., Agarwal R. flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in SENCAR mouse skin tumorigenesis model. Cancer Res. 59:1999;622-632.
37. Zi X., Agarwal R. Anti-proliferative and apoptotic effects of a potent cancer preventive agent silymarin are mediated via distinct signals involving respectively ERK and JNK pathways. Proc. Am. Assoc. Cancer Res. 39:1998;291.
38. Draetta G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem. Sci. 15:1990;378-383.